The effect of Trachyspermum Ammi syrup on the prevention of ventilator-associated pneumonia

Phase 1

Recruiting

Conditions: Ventilator associated pneumonia.
Influenza and pneumonia
J09-J18

Registration Number: IRCT20220204053931N2

Lead Sponsor: Kerman University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Having an oral endotracheal tube
Receiving mechanical ventilation
ICU hospitalization due to trauma

Exclusion Criteria

Having pneumonia at the time of admission
Cardiopulmonary diseases
Lung contusion
Pulmonary thromboembolism
Atelectasis
Inflammatory diseases
Digestive diseases
Liver and biliary diseases
History of allergies to herbal drugs
Symptoms of pulmonary aspiration
Weak immune system
Substance abuse and addiction
Extubation before 10 days
Death or ICU discharge before 10 days
Sudden change in hemodynamic status
Complications such as hives, itching and skin rashes that can be a sign of allergy to Trachyspermum Ammi syrup

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ventilator-associated pneumonia. Timepoint: Ventilator-associated pneumonia will be assessed on the fifth and tenth day of the intervention. Method of measurement: Ventilator-associated pneumonia will be assessed by an infectious disease specialist using the Clinical Lung Infection Scale (CPIS). CPIS includes six criteria, including temperature, white blood cell count, tracheal secretion, oxygenation, culture and smear of tracheal secretion, and chest x-ray. Each of criteria is given a score of zero to two. The maximum score of this tool is 10. VAP is diagnosed if the sum of scores is equal to or greater than 6.

Secondary Outcome Measures